Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma.

Smalley KS, Fedorenko IV.

Mol Cell Oncol. 2015 Mar 19;2(4):e1008291. doi: 10.1080/23723556.2015.1008291. eCollection 2015 Oct-Dec.


A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.

Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, McIntosh L, Caceres G, Magliocco A, Etame A, Harbour JW, Smalley KS, Forsyth PA.

Melanoma Res. 2016 Oct;26(5):481-6. doi: 10.1097/CMR.0000000000000274. Review.


Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA.

Int J Cancer. 2016 Sep 15;139(6):1195-201. doi: 10.1002/ijc.30147. Epub 2016 Apr 30. Review.


The complexity of microenvironment-mediated drug resistance.

Fedorenko IV, Smalley KS.

Genes Cancer. 2015 Sep;6(9-10):367-8. No abstract available.


BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.

Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KSM.

J Invest Dermatol. 2015 Dec;135(12):3115-3124. doi: 10.1038/jid.2015.329. Epub 2015 Aug 24.


Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS.

Oncogene. 2016 Mar 10;35(10):1225-35. doi: 10.1038/onc.2015.188. Epub 2015 Jun 15.


XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.

Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen YA, Kudchadkar RR, Sondak VK, Weber J, Messina JL, Smalley KSM.

J Invest Dermatol. 2015 Oct;135(10):2542-2544. doi: 10.1038/jid.2015.205. Epub 2015 Jun 3. No abstract available.


Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS.

Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26.


Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.

Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS.

Proteomics. 2015 Jan;15(2-3):327-39. doi: 10.1002/pmic.201400200. Epub 2014 Dec 17.


Beyond BRAF: where next for melanoma therapy?

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS.

Br J Cancer. 2015 Jan 20;112(2):217-26. doi: 10.1038/bjc.2014.476. Epub 2014 Sep 2. Review.


Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

Fedorenko IV, Fang B, Koomen JM, Gibney GT, Smalley KS.

Melanoma Res. 2014 Oct;24(5):448-53. doi: 10.1097/CMR.0000000000000103.


Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.

Mol Cell Proteomics. 2014 Jul;13(7):1844-54. doi: 10.1074/mcp.M113.037424. Epub 2014 Apr 23.


Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS.

Pigment Cell Melanoma Res. 2014 May;27(3):465-78. doi: 10.1111/pcmr.12227. Epub 2014 Feb 21.


Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

Sloot S, Fedorenko IV, Smalley KS, Gibney GT.

Expert Opin Pharmacother. 2014 Apr;15(5):589-92. doi: 10.1517/14656566.2014.881471. Epub 2014 Jan 24.


Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.

Kim E, Rebecca V, Fedorenko IV, Messina JL, Mathew R, Maria-Engler SS, Basanta D, Smalley KS, Anderson AR.

Cancer Res. 2013 Dec 1;73(23):6874-85. doi: 10.1158/0008-5472.CAN-13-1720. Epub 2013 Sep 30.


Melanoma genotypes and phenotypes get personal.

Pimiento JM, Larkin EM, Smalley KS, Wiersma GL, Monks NR, Fedorenko IV, Peterson CA, Nickoloff BJ.

Lab Invest. 2013 Aug;93(8):858-67. doi: 10.1038/labinvest.2013.84. Epub 2013 Jul 1. Review.


Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS.

Nat Rev Clin Oncol. 2013 Jul;10(7):390-9. doi: 10.1038/nrclinonc.2013.83. Epub 2013 May 28. Review.


NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Fedorenko IV, Gibney GT, Smalley KS.

Oncogene. 2013 Jun 20;32(25):3009-18. doi: 10.1038/onc.2012.453. Epub 2012 Oct 15. Review.


Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Fedorenko IV, Paraiso KH, Smalley KS.

Biochem Pharmacol. 2011 Aug 1;82(3):201-9. doi: 10.1016/j.bcp.2011.05.015. Epub 2011 May 25. Review.


PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS.

Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11.


Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS.

Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714.


Enhanced imaging and accelerated photothermalysis of A549 human lung cancer cells by gold nanospheres.

Liu X, Lloyd MC, Fedorenko IV, Bapat P, Zhukov T, Huo Q.

Nanomedicine (Lond). 2008 Oct;3(5):617-26. doi: 10.2217/17435889.3.5.617.


Supplemental Content

Loading ...
Support Center